Back to Menu
1. Clinical presentation and medical history
A detailed history is taken regarding symptoms such as headache and seizures to preliminarily assess lesion nature and potential involvement of functional regions.
2. Neurological examination
Assessment of consciousness, motor function, and sensory function provides objective signs for tumor localization.
3. Magnetic resonance imaging (MRI)
The first-line core imaging modality: non-contrast sequences localize the lesion, and contrast enhancement supports assessment of malignancy and grading.
4. Computed tomography (CT) and other imaging
Used for emergency screening for mass effect and hemorrhage; PET helps distinguish recurrence from radiation necrosis.
5. Histopathological biopsy
Microscopic diagnosis using stereotactic biopsy or surgical specimens; the gold standard and enables WHO grading.
6. Molecular pathology testing
Testing markers such as IDH, 1p/19q, and MGMT guides classification, prognostic stratification, and selection of targeted or chemotherapy strategies.
7. Electroencephalography (EEG)
Evaluates seizure type and origin and supports localization of epileptogenic foci.
8. Differential diagnosis
Differentiation from oligodendroglioma, metastatic tumors, and infections is required; imaging–pathology correlation is pivotal.
9. Daily self-check for astrocytoma
The public should remain vigilant for new-onset persistent headache, seizures, limb weakness, language impairment, or personality changes and seek medical evaluation promptly.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that delayed diagnosis of astrocytoma can lead to irreversible neurological deficits and rapid progression to advanced disease, substantially limiting treatment efficacy. Early and accurate diagnosis is a lifeline. Vigilance for neurological abnormalities and early detection through MRI, pathology, and molecular testing are essential. Accurate diagnosis is the fundamental prerequisite for individualized multimodal treatment and improved treatment outcomes.
1. Clinical presentation and medical history
A detailed history is taken regarding symptoms such as headache and seizures to preliminarily assess lesion nature and potential involvement of functional regions.
2. Neurological examination
Assessment of consciousness, motor function, and sensory function provides objective signs for tumor localization.
3. Magnetic resonance imaging (MRI)
The first-line core imaging modality: non-contrast sequences localize the lesion, and contrast enhancement supports assessment of malignancy and grading.
4. Computed tomography (CT) and other imaging
Used for emergency screening for mass effect and hemorrhage; PET helps distinguish recurrence from radiation necrosis.
5. Histopathological biopsy
Microscopic diagnosis using stereotactic biopsy or surgical specimens; the gold standard and enables WHO grading.
6. Molecular pathology testing
Testing markers such as IDH, 1p/19q, and MGMT guides classification, prognostic stratification, and selection of targeted or chemotherapy strategies.
7. Electroencephalography (EEG)
Evaluates seizure type and origin and supports localization of epileptogenic foci.
8. Differential diagnosis
Differentiation from oligodendroglioma, metastatic tumors, and infections is required; imaging–pathology correlation is pivotal.
9. Daily self-check for astrocytoma
The public should remain vigilant for new-onset persistent headache, seizures, limb weakness, language impairment, or personality changes and seek medical evaluation promptly.
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that delayed diagnosis of astrocytoma can lead to irreversible neurological deficits and rapid progression to advanced disease, substantially limiting treatment efficacy. Early and accurate diagnosis is a lifeline. Vigilance for neurological abnormalities and early detection through MRI, pathology, and molecular testing are essential. Accurate diagnosis is the fundamental prerequisite for individualized multimodal treatment and improved treatment outcomes.